This is the authors' abstract. We don't add key points for this paper.
The addition of subcutaneous daratumumab to VRd induction and consolidation therapy and to lenalidomide maintenance therapy conferred a significant benefit with respect to progression-free survival among transplantation-eligible patients with newly diagnosed multiple myeloma. (Funded by the European Myeloma Network in collaboration with Janssen Research and Development; PERSEUS ClinicalTrials.gov number, NCT03710603; EudraCT number, 2018-002992-16.).
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Sonneveld et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: